Jove
Visualize
Contact Us

Related Experiment Videos

Depression and coronary artery disease.

Nancy Frasure-Smith1, François Lespérance

  • 1Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Recherche Psychiatrie, Montréal,Québec, Canada.

Herz
|June 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot randomized trial of intermittent theta-burst stimulation versus H-Coil transcranial magnetic stimulation for treatment-resistant depression.

Psychiatry research·2026
Same author

Virtual reality-based Avatar Therapy for treatment-resistant major depressive disorder: A pilot study.

Psychiatry research·2026
Same author

Modifiers in Effects of Combined Pharmacotherapy and Psychotherapy versus Pharmacotherapy Alone for Adult Depression: An Individual Participant Data Meta-Analysis.

Psychotherapy and psychosomatics·2026
Same author

Canadian Psychiatry Human Resource Planning: Delphi-Method Study of Academic Chairs of Psychiatry of Canada: Planification des ressources humaines en psychiatrie au Canada : étude menée à l'aide des méthodes Delphi auprès des chefs de département de psychiatrie au Canada.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same author

[The Revue Santé mentale au Québec: Sharing knowledge in French].

Sante mentale au Quebec·2023
Same author

Preferences for research design and treatment of comorbid depression among patients with an opioid use disorder: A cross-sectional discrete choice experiment.

Drug and alcohol dependence·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Depression affects up to 20% of cardiac patients, significantly increasing their risk of future heart events. Addressing depression may be a crucial, modifiable cardiac risk factor.

Area of Science:

  • Cardiology
  • Psychiatry
  • Preventive Medicine

Background:

  • Major depression and depressive symptoms are prevalent in patients with coronary artery disease (CAD), occurring at rates three times higher than in the general population.
  • Approximately 12-20% of hospitalized cardiac patients meet criteria for major depression, with a similar percentage reporting elevated depressive symptoms.

Purpose of the Study:

  • To highlight the significant prevalence of depression in patients with CAD.
  • To underscore the association between depression and increased risk of subsequent cardiac events.
  • To explore potential mechanisms linking depression and CAD and the role of omega-3 fatty acids.

Main Methods:

  • Review of studies involving patients recovering from myocardial infarction, unstable angina, coronary bypass surgery, and coronary angioplasty.

Related Experiment Videos

  • Analysis of epidemiological data linking depression and CAD development.
  • Examination of proposed biological mechanisms connecting depression and cardiovascular disease.

    • Main Results:

    • Depression is not a normal response to cardiac disease but a significant risk factor, more than doubling the risk of future cardiac events.
    • Depression can precede the clinical diagnosis of CAD by many years, indicating a potential causal or contributory role.
    • Proposed mechanisms include autonomic dysregulation, inflammation, endothelial dysfunction, and altered platelet activity, with omega-3 fatty acids implicated in both depression and CAD.

    Conclusions:

    • Depression is a highly prevalent and serious comorbidity in CAD patients, acting as a modifiable risk factor.
    • Further clinical trials investigating the impact of omega-3 supplements on depression in both CAD patients and the general population are warranted.